Valuation: Alkermes plc

Capitalization 5.73B 4.83B 4.42B 4.2B 7.79B 520B 8.05B 51B 20.36B 250B 21.5B 21.06B 879B P/E ratio 2025 *
23.7x
P/E ratio 2026 * 21.6x
Enterprise value 4.75B 4.01B 3.67B 3.48B 6.46B 431B 6.68B 42.29B 16.89B 207B 17.83B 17.46B 729B EV / Sales 2025 *
3.23x
EV / Sales 2026 * 3.36x
Free-Float
90.15%
Yield 2025 *
-
Yield 2026 * -
1 day+0.13%
1 week+1.00%
Current month+1.71%
1 month+16.37%
3 months+1.95%
6 months+29.88%
Current year+23.20%
1 week 33.35
Extreme 33.35
35.34
1 month 28.93
Extreme 28.93
35.34
Current year 27.5
Extreme 27.5
35.34
1 year 25.16
Extreme 25.165
36.45
3 years 22.01
Extreme 22.01
36.45
5 years 18.02
Extreme 18.02
36.45
10 years 11.98
Extreme 11.98
71.22
Manager TitleAgeSince
Chief Executive Officer 64 1991-01-31
Director of Finance/CFO 53 2025-09-14
Chief Tech/Sci/R&D Officer - 2004-12-31
Director TitleAgeSince
Chairman 64 2011-08-31
Director/Board Member 74 2016-05-25
Director/Board Member 63 2018-03-29
Change 5d. change 1-year change 3-years change Capi.($)
+0.14%+1.00%+7.85%+24.49% 5.73B
-1.90%-3.65%-16.75%-7.01% 47.36B
-0.55%-0.82%+57.82%+42.45% 39.11B
+5.27%+15.42%+39.15%+61.04% 34.2B
-3.85%-13.18%-12.46%-24.24% 30.94B
+0.54%-0.54%+131.58%+275.84% 18.55B
-4.49%-23.70%+30.68%+87.22% 12.62B
-4.06%-4.63%+27.61%-4.15% 14.17B
-1.01%-2.14%+163.38%+109.67% 13.65B
-0.94%-7.75%+26,532.76%+3,453.20% 13.19B
Average -1.05%-2.73%+2,696.16%+401.85% 22.95B
Weighted average by Cap. -0.74%-1.35%+1,559.51%+244.07%

Financials

2025 *2026 *
Net sales 1.47B 1.24B 1.14B 1.08B 2B 134B 2.07B 13.09B 5.23B 64.2B 5.52B 5.41B 226B 1.82B 1.54B 1.41B 1.34B 2.48B 165B 2.56B 16.22B 6.47B 79.55B 6.84B 6.7B 279B
Net income 246M 208M 190M 181M 335M 22.37B 346M 2.19B 875M 10.75B 924M 905M 37.79B 268M 226M 207M 197M 364M 24.34B 377M 2.39B 952M 11.7B 1.01B 985M 41.11B
Net Debt -978M -825M -755M -717M -1.33B -88.79B -1.37B -8.7B -3.47B -42.69B -3.67B -3.59B -150B 384M 324M 296M 282M 522M 34.87B 540M 3.42B 1.36B 16.77B 1.44B 1.41B 58.91B
Logo Alkermes plc
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Employees
1,800
Date Price Change Volume
26-02-11 34.46 $ -0.73% 329,577
26-02-10 34.72 $ -0.34% 1,520,346
26-02-09 34.84 $ -0.20% 1,415,785
26-02-06 34.91 $ +4.05% 1,938,870
26-02-05 33.55 $ -1.70% 1,572,384
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
34.72USD
Average target price
43.81USD
Spread / Average Target
+26.19%

Quarterly revenue - Rate of surprise